1. Home
  2. CYTK vs HSIC Comparison

CYTK vs HSIC Comparison

Compare CYTK & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$63.24

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Logo Henry Schein Inc.

HSIC

Henry Schein Inc.

HOLD

Current Price

$78.76

Market Cap

9.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYTK
HSIC
Founded
1997
1932
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
9.1B
IPO Year
2004
1995

Fundamental Metrics

Financial Performance
Metric
CYTK
HSIC
Price
$63.24
$78.76
Analyst Decision
Strong Buy
Hold
Analyst Count
16
14
Target Price
$83.69
$76.29
AVG Volume (30 Days)
2.1M
1.2M
Earning Date
02-26-2026
02-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.70
EPS
N/A
3.17
Revenue
$87,211,000.00
$12,938,000,000.00
Revenue This Year
$339.72
$5.34
Revenue Next Year
$79.08
$3.42
P/E Ratio
N/A
$24.53
Revenue Growth
2609.26
3.51
52 Week Low
$29.31
$60.56
52 Week High
$70.98
$82.49

Technical Indicators

Market Signals
Indicator
CYTK
HSIC
Relative Strength Index (RSI) 50.19 57.81
Support Level $61.10 $77.53
Resistance Level $65.35 $79.97
Average True Range (ATR) 3.03 2.08
MACD 0.00 -0.05
Stochastic Oscillator 58.49 78.02

Price Performance

Historical Comparison
CYTK
HSIC

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About HSIC Henry Schein Inc.

Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.

Share on Social Networks: